NASDAQ
0.84USD
-0.01 (-0.84%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
16.7M
P/E
—
EPS
—
Beta
-0.25
52W range
0.475-1.23
Day range
0.81–0.85
Open
0.85
Prev close
0.84
Volume
771.6K
Avg volume
396.4K
Dividend
0.00
IPO
2021-02-12
https://www.benzinga.com/trading-ideas/long-ideas/26/08/61401151/dicks-sporting-goods-intuit-and-3-stocks-to-watch-heading-into-tuesday · 8/25/2026-0.80
https://seekingalpha.com/article/4919247-longeveron-inc-lgvn-shareholder-analyst-call-prepared-remarks-transcript · 7/1/2026+0.00
https://www.globenewswire.com/news-release/2026/03/17/3257647/0/en/Longeveron-Announces-2025-Full-Year-Financial-Results-and-Provides-Business-Update.html · 3/17/2026+0.60
https://www.benzinga.com/trading-ideas/movers/26/03/51308659/longeveron-braces-for-q4-results-following-recent-funding-boost · 3/17/2026+0.60
https://www.globenewswire.com/news-release/2025/11/19/3191065/0/en/Longeveron-Laromestrocel-Data-in-Alzheimer-s-Disease-Selected-for-Poster-Presentation-at-the-Clinical-Trials-on-Alzheimer-s-Disease-Conference-CTAD-2025.html · 11/19/2025
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
